---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-123974"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-12-23T23:59:59+00:00"
generated_at: "2026-05-16T12:14:48.537469+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ironwood subsidiary settles Ferring IP litigation with $12.5M payment, license amendment

## Summary
- VectivBio to pay Ferring $12.5M ($7.5M upfront, $5M by Dec 31, 2026) under amended license.
- High single-digit royalty on net sales for 7 years after first commercial sale, then low single-digit royalty.
- Amendment resolves Ferring's trade secret misappropriation lawsuit in E.D. Tex.
- Ironwood guarantees VectivBio's $12.5M payment obligations under the amendment.
- Clarified ownership of Contested Patents and Arising Intellectual Property exclusively to VectivBio.

## SEC filing metadata
- accession: 0001104659-25-123974
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-12-23T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925123974/0001104659-25-123974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925123974/tm2534055d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-123974
- JSON: https://secwatch.observer/filing/0001104659-25-123974.json
- Plain text: https://secwatch.observer/filing/0001104659-25-123974.txt

## Key facts
- Material Agreements
  IRONWOOD PHARMACEUTICALS INC amended Third Amendment to Amended and Restated Exclusive License Agreement with Ferring International Center S.A. valued at $12.5 million aggregate payment to Ferring, including an initial payment of $7.5 million and a secon (effective 2025-12-18).
  - Action: amendment
  - Agreement: license
  - Counterparty: Ferring International Center S.A.
  - Value: $12.5 million aggregate payment to Ferring, including an initial payment of $7.5 million and a secon
  - Effective: 2025-12-18
  source text: On December 18, 2025, Ironwood Pharmaceuticals, Inc. (the "Company"), solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company ("VectivBio"), and Ferring International Center S.A. ("Ferring"), entered into that certain third amendment (the "Amendment") to the amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and between GlyPharma Therapeutic Inc. (as predecessor to VectivBio) and Ferring (the "Ferring License Agreement").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465925123974/0001104659-25-123974-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.